BBIO Stock Discussion
BridgeBio Pharma, Inc. Description
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Industry: Biotechnology
Keywords: Organ Systems Clinical Development Protein Kinase Inhibitor Tyrosine Kinase Tyrosine Kinase Receptors Amyloid Amyloidosis Cardiomyopathy Hyperplasia Fibroblast Growth Factor Receptor Myopathy Transthyretin Achondroplasia Congenital Adrenal Hyperplasia Familial Amyloid Polyneuropathy Polyneuropathy TTR Amyloidosis
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Popular Now
Featured Articles